Market Research Report
Age Related Macular Degeneration - Pipeline Review, H1 2018
|Published by||Global Markets Direct||Product code||213105|
|Published||Content info||531 Pages
Delivery time: 1-2 business days
|Age Related Macular Degeneration - Pipeline Review, H1 2018|
|Published: June 15, 2018||Content info: 531 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Age Related Macular Degeneration - Pipeline Review, H1 2018, provides an overview of the Age Related Macular Degeneration (Ophthalmology) pipeline landscape.
Age related macular degeneration is the most common reason for vision loss in people aged above 50. It results in depreciation of the macula that may lead to distorted or blurry central vision. The predisposing factors involved are age, smoking, sunlight, heredity etc. Symptoms include development of blind spot and hazy vision. The condition may be treated by photodynamic therapy, radiation therapy and medication such as anti-angiogenic drugs.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Age Related Macular Degeneration - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Age Related Macular Degeneration (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Age Related Macular Degeneration (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Age Related Macular Degeneration and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 28, 19, 3, 145, 24 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 14 and 1 molecules, respectively.
Age Related Macular Degeneration (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.